Pharmaceuticals

Sustained Release Excipients Market to Grow at a CAGR of 8.5% from 2025 to 2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Sustained Release Excipients Market Covering 2025–2034?

The sustained release excipients market has demonstrated significant expansion in recent years. Its value is projected to rise from $1.4 billion in 2024 to $1.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%. This historical market expansion stems from factors such as a greater need for controlled drug release, the widespread occurrence of chronic illnesses, enhanced patient compliance and convenience, ongoing innovations in the pharmaceutical sector, and supportive regulations for extended-release formulations.

The sustained release excipients market is projected to experience substantial expansion over the upcoming years, with its size predicted to reach $2.1 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.5%. Key drivers behind this anticipated growth include the expanding elderly demographic, an emphasis on tailored medicine, difficulties with patient compliance, the proliferation of intricate drug formulations, improvements in disease treatment, and the worldwide growth of healthcare. Significant developments expected during this timeframe encompass drug delivery centered on patients, joint ventures for formulation creation, adherence to regulations and safety standards, the worldwide spread of drug formulation techniques, and the impact of biopharmaceutical products.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What Are The Drivers Pushing New Developments In The Sustained Release Excipients Market?

The future expansion of the sustained-release excipients market is anticipated to be driven by the increasing incidence of chronic and acute diseases. These illnesses represent two distinct classifications based on their duration and progression. Chronic conditions are long-term health issues persisting typically for three months or more, while acute conditions are characterized by a sudden onset of symptoms that are usually severe but short-lived, lasting from hours to days or weeks. Sustained-release excipients are extensively utilized in pharmaceutical formulations for both chronic and acute ailments, as they enhance patient adherence, maintain stable drug levels, mitigate side effects, and improve overall disease management, thereby boosting their sales. For instance, data from September 2022, provided by the World Health Organization (WHO), a specialized health agency based in Switzerland, indicated that cardiovascular diseases were responsible for the majority of NCD deaths, accounting for 17.9 million individuals annually. This was followed by chronic respiratory illnesses at 4.1 million, cancer at 9.3 million, and diabetes, including fatalities from renal disease associated with diabetes, at 2.0 million. Furthermore, a report released in August 2022 by the American College of Cardiology, a US-based non-profit medical association, projected a rise in all four major cardiovascular risk factors in the United States between 2025 and 2060. Diabetes is projected to experience the most significant percentage increase, with a 39.3% rise to 55 million people, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Additionally, substantial increases in cardiovascular disease rates are expected for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) also seeing considerable growth. Consequently, the rising prevalence of chronic and acute diseases is a key factor propelling the sustained-release excipients market forward.

What Are The Major Segment Categories Driving The Sustained Release Excipients Market Growth?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Market Trends Are Creating New Opportunities In The Sustained Release Excipients Industry?

Product innovation is a key trend gaining traction in the sustained release excipients market. Leading companies operating in the sustained release excipients market are developing new products to solidify their market position. For example, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, launched Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). This advanced Ashwagandha root-only extract offers continuous support for stress reduction. Prolanza’s unique release mechanism enables it to demonstrate its therapeutic effects over an extended period with just one dose each day. When compared to the control component, Prolanza ashwagandha exhibited better relative absorption, improved bioavailability, and a longer elimination half-life, indicating a sustained-release profile. Because ashwagandha is primarily utilized for its ability to adapt and lessen stress responses, Prolanza’s therapeutic effects are expected to last longer and have a greater overall positive influence on health. It is made from natural herbs and has been clinically proven to work.

Who Are The Prominent Global Companies Shaping The Sustained Release Excipients Market?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

How Is Sustained Release Excipients Market Demand Varying Across Different Regions?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Sustained Release Excipients Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2025, By The Business Research Company

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Telemedicine Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/telemedicine-services-global-market-report

Animal Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795